Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M32.3Revenue (TTM) $M63.4Net Margin (%)-120.8Altman Z-Score-5.8
Enterprise Value $M118EPS (TTM) $-7.2Operating Margin %-151.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score0.3Pre-tax Margin (%)-120.6Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-31.2Quick Ratio2.4Cash flow > EarningsN
Price/Sales0.55-y EBITDA Growth Rate %-32.1Current Ratio2.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-26.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-542.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.4ROIC % (ttm)-89.0Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OREX is held by these investors:



OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Moglia Stephen A.VP, Chief Accounting Officer 2016-12-19Sell800$1.966.63view
Booth Mark DChief Commercial Officer 2015-02-26Sell5,000$56.8-96.32view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell2,264$60-96.52view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell3,139$58.3-96.42view
BOCK LOUIS CDirector 2014-11-18Buy133$55.8-96.25view
BOCK LOUIS CDirector 2014-11-12Buy2,705$55.7-96.25view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell30,000$44.7-95.32view
NARACHI MICHAELPresident and CEO 2014-09-15Buy5,000$47.8-95.63view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy500$46.9-95.54view
Hagan Joseph PChief Business Officer 2013-07-31Sell1,200$78-97.32view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Con Sep 13 2017 
Orexigen Therapeutics to Speak at Upcoming Investor Conferences Aug 29 2017 
Orexigen Therapeutics Announces Second Quarter 2017 Financial Results Aug 08 2017 
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm A Aug 07 2017 
Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contra Jul 26 2017 
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results o Jul 25 2017 
Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Jul 10 2017 
Orexigen Announces Activities at European Congress on Obesity 2017 May 16 2017 
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 May 09 2017 
Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcar May 02 2017 

More From Other Websites
No related articles found.

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}